TYRA Stock Forecast: Tyra Biosciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$20
+1.93% on the day

The 15 Wall Street analysts covering Tyra Biosciences, Inc. hold a median 12-month price target of $50 — +148.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.4B
Ticker Nerd rank
28/ 100
Median analyst target
$50
Analysts covering
15
Revenue$0.0
Operating income−$49.0M
Net income−$45.6M
Free cash flow−$31.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.4%
1M
−1.8%
YTD
−23.5%
1Y
−4.2%
From 52W high
−49.2%
From 52W low
+8.6%
$19
$40
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Tyra Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
82
Momentum
71
Value
52
Accruals
39
Quality
36
Issuance
34
Revisions
29
Growth
22

Volatility (82): The share price has been relatively steady.

Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TYRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TYRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26TYRAHigh $59Median $50Low $27

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14
Buy
1
Hold
0
Sell
$27
Low
$50
Median
$59
High

The green dot is the last close — the median target sits +148.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
20 Nov 2026GuggenheimAssumesBuy$54 → $55
11 Nov 2026HC Wainwright & Co.MaintainsBuy$29 → $27
11 Nov 2026WedbushMaintainsOutperform$53 → $57
22 Sept 2026HC Wainwright & Co.MaintainsBuy$30 → $29
22 Sept 2026OppenheimerReiteratesOutperform$50 → $40
10 Sept 2026HC Wainwright & Co.MaintainsBuy$45 → $30
10 Sept 2026WedbushReiteratesOutperform$53
4 Sept 2026HC Wainwright & Co.ReiteratesBuy$45
17 June 2026Jones TradingInitiatesBuy$56
10 June 2026B of A SecuritiesMaintainsBuy$37 → $42
19 May 2026Wolfe ResearchInitiatesPeer Perform—
14 May 2026HC Wainwright & Co.ReiteratesBuy—
15 Apr 2026GuggenheimInitiatesBuy—
6 Apr 2026Canaccord GenuityInitiatesBuy—
20 Mar 2026Piper SandlerMaintainsOverweight—
24 Feb 2026Cantor FitzgeraldInitiatesOverweight—
17 Feb 2026HC Wainwright & Co.MaintainsBuy—
13 Feb 2026WedbushMaintainsOutperform—
3 Feb 2026JefferiesMaintainsBuy—
3 Feb 2026OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TYRA.

Market Radar

This page is one stock. Monday covers all of them.

TYRA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TYRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Tyra Biosciences, Inc. returned −4.2% against +6.9% for the S&P 500, dividends included.

TYRA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26TYRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TYRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−34.9%

Higher than 26% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tyra Biosciences, Inc. has a market value of $1.4B and an enterprise value of $694.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$148.6M.

  • Diluted earnings per share, trailing twelve months: −$2.40.

  • Free cash flow in the twelve months to 30 June 2026: −$109.9M.

  • Shares outstanding: 59.7M.

  • Tyra Biosciences, Inc. employs 87 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

TYRA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TYRATyra Biosciences, Inc.$1.4B28
ANABAnaptysBio, Inc.$1.4B90
RAPPRapport Therapeutics, Inc.$1.4B66
NTLAIntellia Therapeutics, Inc.$1.4B27
DMRADamora Therapeutics, Inc.$1.4B44
ADRXADARx Pharmaceuticals, Inc.$1.4B0
NRIXNurix Therapeutics, Inc.$1.4B93

Take a look at TYRA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Tyra Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about TYRA

What is the TYRA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Tyra Biosciences, Inc. have a median 12-month price target of $50, with estimates ranging from $27 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TYRA stock a buy right now?

Of the 15 analysts covering Tyra Biosciences, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tyra Biosciences, Inc. 28 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TYRA?

As at 21 Nov 2026, Tyra Biosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (82 of 100).

Will TYRA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +148.6% from the last close, and Ticker Nerd's factor model ranks Tyra Biosciences, Inc. 28 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TYRA stock forecast for 2030?

No analyst covering Tyra Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TYRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $59 over the next 12 months.

How has TYRA stock performed over the past year?

Tyra Biosciences, Inc. returned -4.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tyra Biosciences, Inc. do?

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization.

Company

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization. Tyra Biosciences is advancing oral dabogratinib across urologic cancers and skeletal dysplasia programs, alongside other FGFR-targeted candidates in its pipeline. Its current business is built around clinical development, translational research, and precision oncology, with an emphasis on conditions where specific genetic alterations drive disease. Headquartered in Carlsbad, California, Tyra Biosciences operates as a focused biotechnology developer serving the oncology and rare disease markets.

CEO Dr. Todd Harris Ph.D. · 87 employees · United States · https://tyra.bio